Tandem Diabetes Care’s Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes
Tandem Diabetes Care, Inc. (TNDM)
Last tandem diabetes care, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.tandemdiabetes.com
Company Research
Source: Business Wire
First and only commercially available AID technology for pregnancy use in the U.S. SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that the United States Food and Drug Administration (FDA) has cleared Control-IQ+ automated insulin delivery (AID) technology for use in pregnancy complicated by type 1 diabetes mellitus. Control-IQ+ powers both insulin delivery systems from Tandem – the t:slim X2 and Tandem Mobi, the first and only commercially available AID systems cleared for use during pregnancy in the United States.“Glycemic goals are tighter during pregnancy,” said Dr. Jordan Pinsker, chief medical officer at Tandem Diabetes Care. “The higher time in the pregnancy-specific glucose range seen with Control-IQ can help improve pregnancy outcomes.”This expanded label indication for use in type 1 diabetes during pregnancy1 is based on results from the CIRCUIT trial published in Journal of
Show less
Read more
Impact Snapshot
Event Time:
TNDM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNDM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNDM alerts
High impacting Tandem Diabetes Care, Inc. news events
Weekly update
A roundup of the hottest topics
TNDM
News
- Tandem Diabetes Care Announces Upcoming Conference PresentationsBusiness Wire
- Tandem Diabetes Care (TNDM) was upgraded by Zacks Research from "hold" to "strong-buy".MarketBeat
- Tandem Diabetes Care (TNDM) was given a new $45.00 price target by Rothschild & Co Redburn.MarketBeat
- Tandem Diabetes Care (TNDM) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
- Tandem Diabetes Care (TNDM) had its price target lowered by The Goldman Sachs Group, Inc. from $28.00 to $25.00. They now have a "neutral" rating on the stock.MarketBeat
TNDM
Earnings
- 2/19/26 - Beat
TNDM
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/17/26 - Form 4
- 4/8/26 - Form ARS
- TNDM's page on the SEC website